Crinetics Pharmaceuticals, Inc. CRNX
We take great care to ensure that the data presented and summarized in this overview for Crinetics Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRNX
View all-
Vanguard Group Inc Valley Forge, PA9.09MShares$340 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.95MShares$260 Million0.07% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$233 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$230 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$203 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$161 Million10.24% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.08MShares$153 Million1.11% of portfolio
-
State Street Corp Boston, MA2.99MShares$112 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.8MShares$105 Million0.08% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.79MShares$104 Million0.34% of portfolio
Latest Institutional Activity in CRNX
Top Purchases
Top Sells
About CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Insider Transactions at CRNX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
5,000
-13.61%
|
$195,000
$39.07 P/Share
|
|
Feb 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+11.98%
|
$80,000
$16.89 P/Share
|
|
Jan 07
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+7.3%
|
$47,500
$19.64 P/Share
|
|
Jan 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
15,000
-33.9%
|
$780,000
$52.09 P/Share
|
|
Jan 03
2025
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+25.32%
|
$240,000
$16.89 P/Share
|
|
Dec 16
2024
|
Stephen F. Betz Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,331
+3.16%
|
$2,331
$1.91 P/Share
|
|
Dec 02
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Indirect |
10,000
-9.09%
|
$570,000
$57.57 P/Share
|
|
Nov 22
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
501
-0.96%
|
$28,056
$56.52 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-33.52%
|
$776,250
$54.63 P/Share
|
|
Oct 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.11%
|
$230,000
$16.89 P/Share
|
|
Sep 26
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
25,000
-18.37%
|
$1,275,000
$51.11 P/Share
|
|
Sep 26
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+15.52%
|
$375,000
$15.29 P/Share
|
|
Sep 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,035
-1.49%
|
$52,785
$51.5 P/Share
|
|
Aug 26
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-4.13%
|
$159,000
$53.19 P/Share
|
|
Aug 12
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.97%
|
$141,000
$47.68 P/Share
|
|
Jul 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.82%
|
$159,000
$53.43 P/Share
|
|
Jul 25
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
19,056
-14.64%
|
$1,009,968
$53.88 P/Share
|
|
Jul 25
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,056
+12.77%
|
$171,504
$9.28 P/Share
|
|
Jul 15
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
27,000
-34.33%
|
$1,485,000
$55.0 P/Share
|
|
Jul 15
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
26,073
+10.18%
|
$547,533
$21.21 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 200K shares |
|---|---|
| Exercise of conversion of derivative security | 525K shares |
| Payment of exercise price or tax liability | 26.8K shares |
|---|---|
| Open market or private sale | 548K shares |
| Bona fide gift | 350 shares |